Figure 1.
Purification of the fibrinolytic enzyme from Coprinus comatus. The elution profile of (A) Octyl-Sepharose Fast Flow hydrophobic interaction chromatography, (B) SP-Sepharose High Performance ion exchange chromatography, and (C) Source 15 PHE hydrophobic interaction chromatography.
Figure 1.
Purification of the fibrinolytic enzyme from Coprinus comatus. The elution profile of (A) Octyl-Sepharose Fast Flow hydrophobic interaction chromatography, (B) SP-Sepharose High Performance ion exchange chromatography, and (C) Source 15 PHE hydrophobic interaction chromatography.
Figure 2.
Molecular weight determination by SDS-PAGE under denaturing conditions. Lane 1: molecular weight standards; Lane 2: the purified enzyme.
Figure 2.
Molecular weight determination by SDS-PAGE under denaturing conditions. Lane 1: molecular weight standards; Lane 2: the purified enzyme.
Figure 3.
Analysis of the purity of CFE. Lane 1: fibrin zymography; Lane 2: Native-PAGE; Lane 3: the imprint of CFE on a fibrin plate.
Figure 3.
Analysis of the purity of CFE. Lane 1: fibrin zymography; Lane 2: Native-PAGE; Lane 3: the imprint of CFE on a fibrin plate.
Figure 4.
Effects of temperature and pH on fibrinolytic activity of CFE. (A) Optimal temperature. (B) Temperature stability. (C) Optimal pH. (D) pH stability.
Figure 4.
Effects of temperature and pH on fibrinolytic activity of CFE. (A) Optimal temperature. (B) Temperature stability. (C) Optimal pH. (D) pH stability.
Figure 5.
Analysis of plasminogen activation by CFE on (A) plasminogen-positive fibrin plate and (B) plasminogen-negative fibrin plate. Circles 1–3 represent CFE; circles 4–5 represent urokinase.
Figure 5.
Analysis of plasminogen activation by CFE on (A) plasminogen-positive fibrin plate and (B) plasminogen-negative fibrin plate. Circles 1–3 represent CFE; circles 4–5 represent urokinase.
Figure 6.
Effect of simulated gastric and blood environments on the CFE. Sample 1, CFE in water (control); sample 2, CFE in artificial gastric juice; sample 3, CFE in gastric juices with a pH of 7.4; sample 4, CFE in artificial gastric juice and broth; sample 5, CFE in artificial gastric juice and saccharose; sample 6, CFE in artificial gastric juice, saccharose, and protein broth; sample 7, CFE in Locke solution. Different letters indicate significant differences (p < 0.05).
Figure 6.
Effect of simulated gastric and blood environments on the CFE. Sample 1, CFE in water (control); sample 2, CFE in artificial gastric juice; sample 3, CFE in gastric juices with a pH of 7.4; sample 4, CFE in artificial gastric juice and broth; sample 5, CFE in artificial gastric juice and saccharose; sample 6, CFE in artificial gastric juice, saccharose, and protein broth; sample 7, CFE in Locke solution. Different letters indicate significant differences (p < 0.05).
Figure 7.
Analysis of thrombin-like activity of CFE. 1, control fibrin clot (human blood fibrinogen and human thrombin); 2, CFE, human blood fibrinogen, and human thrombin; 3, human blood fibrinogen and CFE.
Figure 7.
Analysis of thrombin-like activity of CFE. 1, control fibrin clot (human blood fibrinogen and human thrombin); 2, CFE, human blood fibrinogen, and human thrombin; 3, human blood fibrinogen and CFE.
Figure 8.
Cleavage pattern of fibrin(ogen) by CFE; (A) SDS-PAGE analysis of human blood fibrinogen hydrolyzed by CFE. Lane C, control; Lanes 1–10, degradation pattern of fibrinogen at different time intervals of 1 min, 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, and 5 h, respectively. (B) SDS-PAGE analysis of human fibrin hydrolyzed by CFE; Lane C, control; Lanes 1–9, degradation pattern of fibrin at different time intervals of 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, and 5 h, respectively.
Figure 8.
Cleavage pattern of fibrin(ogen) by CFE; (A) SDS-PAGE analysis of human blood fibrinogen hydrolyzed by CFE. Lane C, control; Lanes 1–10, degradation pattern of fibrinogen at different time intervals of 1 min, 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, and 5 h, respectively. (B) SDS-PAGE analysis of human fibrin hydrolyzed by CFE; Lane C, control; Lanes 1–9, degradation pattern of fibrin at different time intervals of 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, and 5 h, respectively.
Figure 9.
Effects of CFE on some blood proteins. Lanes 1, 3, and 5 represent human thrombin, IgG, and human serum albumin (HSA), respectively. Lanes 2, 4, and 6 represent human thrombin, IgG, and HSA incubated with CFE, respectively.
Figure 9.
Effects of CFE on some blood proteins. Lanes 1, 3, and 5 represent human thrombin, IgG, and human serum albumin (HSA), respectively. Lanes 2, 4, and 6 represent human thrombin, IgG, and HSA incubated with CFE, respectively.
Figure 10.
Effects of CFE on coagulation index in vitro. The levels of (A) APTT, (B) PT, (C) PA, (D) TT, and (E) FIB in different experimental groups. Different letters indicate significant differences (p < 0.05).
Figure 10.
Effects of CFE on coagulation index in vitro. The levels of (A) APTT, (B) PT, (C) PA, (D) TT, and (E) FIB in different experimental groups. Different letters indicate significant differences (p < 0.05).
Figure 11.
Anticoagulant activity of CFE. (1) Plasma and heparin; (2) plasma and saline; (3) plasma and CFE.
Figure 11.
Anticoagulant activity of CFE. (1) Plasma and heparin; (2) plasma and saline; (3) plasma and CFE.
Table 1.
The experimental method of simulated blood and gastric environment.
Table 1.
The experimental method of simulated blood and gastric environment.
Group | Composition |
---|
1 | 100 μL H2O, 50 μL CFE |
2 | 100 μL gastric juice, 50 μL CFE |
3 | 100 μL gastric juice with a pH of 7.4, 50 μL CFE |
4 | 50 μL gastric juice, 50 μL of broth, 50 μL CFE |
5 | 50 μL gastric juice, 50 μL 10% saccharose, 50 μL CFE |
6 | 50 μL gastric juice, 25 μL broth, 25 μL 10% saccharose, 50 μL CFE |
7 | 100 μL Locke solution, 50 μL CFE |
Table 2.
The experimental method for the analysis of thrombin-like activity.
Table 2.
The experimental method for the analysis of thrombin-like activity.
Group | Composition |
---|
1 | Human blood fibrinogen (10 mg/mL), human thrombin (200 U/mL) |
2 | Human blood fibrinogen (10 mg/mL), human thrombin (200 U/mL), CFE (72 U/mL) |
3 | Human blood fibrinogen (10 mg/mL), CFE (72 U/mL) |
Table 3.
The experimental method for the analysis of anticoagulant activity.
Table 3.
The experimental method for the analysis of anticoagulant activity.
Group | Composition |
---|
Blank control group | 500 μL PPP |
Negative control group | 500 μL PPP, 500 μL normal saline |
Positive control group | 500 μL PPP, 500 μL heparin sodium (30 U/mL) |
CFE low-dose group | 500 μL PPP, 500 μL CFE (10 U/mL) |
CFE high-dose group | 500 μL PPP, 500 μL CFE (30 U/mL) |
Table 4.
Purification steps of the fibrinolytic enzyme from Coprinus comatus.
Table 4.
Purification steps of the fibrinolytic enzyme from Coprinus comatus.
Purification Steps | Volume | Protein | Activity | Recovery | Specific Activity | Purification Fold |
---|
| mL | mg | U | % | U·mg−1 | |
---|
Crude enzyme | 200.00 | 1684.00 | 25,286.00 | 100.00 | 15.02 | 1.00 |
60% (NH4)2SO4 | 50.00 | 293.00 | 21,847.00 | 86.40 | 74.56 | 4.97 |
Octyl-FF | 69.00 | 40.02 | 18,415.41 | 72.83 | 460.16 | 30.65 |
G-25 | 120.00 | 27.60 | 16,098.00 | 63.66 | 583.26 | 38.84 |
SP-HP | 28.00 | 4.48 | 6943.44 | 27.46 | 1907.54 | 127.04 |
Source 15PHE | 7.00 | 0.69 | 2533.30 | 10.02 | 3619.00 | 241.02 |
Table 5.
Comparison of N-terminal sequence of CFE.
Table 5.
Comparison of N-terminal sequence of CFE.
Source | Position of First Amino Acid | Sequence | Identity (%) | Accession Number |
---|
Coprinus comatus | | ATYTGGSQT | | This study |
Prevotella sp. | 90 | TYTGGSQT | 88% | MBP1540255.1 |
Mytilus galloprovincialis | 536 | TYTGGSQT | 89% | VDI71986.1 |
Clostridium saccharoperbutylacetonicum | 205 | ATYTGGAQT | 89% | WP_015393369.1 |
Prolixibacteraceae bacterium | 321 | ATYTGGTQT | 88% | HBL77885.1 |
Table 6.
Effects of some metal ions on the fibrinolytic activity of CFE.
Table 6.
Effects of some metal ions on the fibrinolytic activity of CFE.
Metal Ions | Residual Fibrinolytic Activity (%) |
---|
Control | 100 |
Zn2+ | 154.51 ± 2.21 |
Fe2+ | 11.75 ± 0.53 |
Cu2+ | 95.74 ± 0.93 |
Fe3+ | 40.45 ± 0.64 |
K+ | 110.89 ± 3.63 |
Ca2+ | 173.20 ± 1.17 |
Na+ | 97.85 ± 2.93 |
Mn2+ | 146.33 ± 3.01 |
Al2+ | 30.28 ± 0.87 |
Mg2+ | 108.50 ± 3.16 |
Ba2+ | 76.18 ± 3.27 |
Table 7.
Effects of protease inhibitors on the fibrinolytic activity of CFE.
Table 7.
Effects of protease inhibitors on the fibrinolytic activity of CFE.
Inhibitor | Concentration (mmol/L) | Residual Fibrinolytic Activity (%) |
---|
Control | | 100 |
Aprotinine | 10 | 85.53 ± 1.27 |
5 | 97.89 ± 2.26 |
2.5 | 104.88 ± 1.63 |
1 | 107.03 ± 1.81 |
PMSF | 10 | 12.98 ± 2.11 |
5 | 24.26 ± 1.82 |
2.5 | 30.46 ± 3.21 |
1 | 39.12 ± 2.93 |
TPCK | 10 | 87.21 ± 1.39 |
5 | 90.03 ± 2.22 |
2.5 | 105.76 ± 2.31 |
1 | 98.11 ± 1.97 |
Pepstatin | 10 | 92.37 ± 1.34 |
5 | 94.82 ± 1.41 |
2.5 | 97.20 ± 1.68 |
1 | 98.32 ± 2.08 |
EDTA | 10 | 0.00 |
5 | 0.00 |
2.5 | 0.00 |
1 | 0.00 |
SBTI | 10 | 47.19 ± 2.36 |
5 | 58.42 ± 1.83 |
2.5 | 79.46 ± 1.96 |
1 | 91.67 ± 2.21 |
Table 8.
Effects of some reagents on the fibrinolytic activity of CFE.
Table 8.
Effects of some reagents on the fibrinolytic activity of CFE.
Reagent | Concentration | Residual Fibrinolytic Activity (%) |
---|
Control | | 100 |
Cysteine | 20 mmol/L | 97.85 ± 3.27 |
Reduced glutathione | 5 mmol/L | 92.62 ± 2.83 |
Oxidized glutathione | 5 mmol/L | 96.34 ± 2.75 |
β-mercaptoethanol | 0.50% | 97.02 ± 2.48 |
Peptone | 1% | 103.08 ± 2.74 |
Gelatin | 1% | 149.91 ± 1.29 |
Bovine serum albumin | 1% | 80.61 ± 2.39 |
Acetone | 10% | 89.95 ± 1.86 |
Glycerol | 10% | 168.78 ± 1.95 |
SDS | 0.30% | 4.64 ± 0.22 |
Urea | 8 mol/L | 45.33 ± 3.08 |
Table 9.
Analysis of dissolution of blood clots by CFE at different time intervals.
Table 9.
Analysis of dissolution of blood clots by CFE at different time intervals.
Time | Weight (g) | Dissolution Rate (%) |
---|
0 | 0.5058 ± 0.0062 | 0.00 |
10 min | 0.4713 ± 0.0058 | 6.82 |
20 min | 0.4082 ± 0.0047 | 19.30 |
40 min | 0.3647 ± 0.0039 | 27.90 |
60 min | 0.3329 ± 0.0042 | 34.18 |
90 min | 0.3183 ± 0.0028 | 37.07 |
120 min | 0.2803 ± 0.0036 | 44.58 |
150 min | 0.2436 ± 0.0048 | 51.84 |
180 min | 0.2229 ± 0.0052 | 55.93 |
12 h | 0.1728 ± 0.0041 | 65.84 |
24 h | 0.0882 ± 0.0032 | 82.56 |